Origenis Receives Grant to Develop New Diagnostic Tools
News Feb 29, 2012
LRRK2 inhibitors are expected to be useful for the treatment of Parkinson’s disease and other neurodegenerative disorders.
The objective of this biomarker program is the development of fluorine labelled, LRRK2 specific, CNS penetrating compounds that will be used to visualize the disease progression in animal Parkinson’s models.
Origenis receives a two-years-grant from the Leading-Edge Cluster program “m4 – Personalized Medicine and Targeted Therapies”.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE